Serum Creatinine and Albumin Correlate with Survival in ALS

Serum creatinine and albumin as well as absolute lymphocyte count at the time of amyotrophic lateral sclerosis diagnosis correlate with 1-year survival.

The development of effective treatments for patients with amyotrophic lateral sclerosis (ALS) has proven to be immensely challenging. Among the many challenges to therapeutic development is the variability in the natural history of the disease, along with a paucity of biological markers that might forecast future prognosis. Factors previously shown to predict a poor outcome include a short latency from symptom onset to diagnosis, older age, female gender, bulbar (vs. limb) onset, and the presence of respiratory muscle weakness. Scientists have now investigated the utility of an array of routine hematological and biochemical factors at the time of ALS diagnosis in predicting 1-year survival in a population-based cohort of 639 patients and a …

Reviewing Author

Michael Benatar, MD, MS, PhD

Disclosures

Grant / Research supportNIH NeuroBioBank; ALS Association; NIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences; FDA; Department of Defense

Editorial boardsCochrane Collaboration

Leadership positions in professional societiesMuscle Study Group Executive Committee

Michael Benatar, MD, MS, PhD

Disclosures

Editorial boardsCochrane Collaboration

Leadership positions in professional societiesMuscle Study Group Executive Committee

Serum Creatinine and Albumin Correlate with Survival in ALS

Topics

Reviewing Author